PT - JOURNAL ARTICLE AU - Huiberts, Anne J. AU - Hoeve, Christina E. AU - de Gier, Brechje AU - Cremer, Jeroen AU - van der Veer, Bas AU - de Melker, Hester E. AU - van de Wijgert, Janneke H.H.M. AU - van den Hof, Susan AU - Eggink, Dirk AU - Knol, Mirjam J. TI - Effectiveness of Omicron XBB.1.5 vaccine against SARS-CoV-2 Omicron XBB and JN.1 infection in a prospective cohort study in the Netherlands, October 2023 to January 2024 AID - 10.1101/2024.02.15.24302872 DP - 2024 Jan 01 TA - medRxiv PG - 2024.02.15.24302872 4099 - http://medrxiv.org/content/early/2024/02/17/2024.02.15.24302872.short 4100 - http://medrxiv.org/content/early/2024/02/17/2024.02.15.24302872.full AB - We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95%CI:23-55) in 18-59-year-olds and 50% (95%CI:44-56) in 60-85-year-olds. Sequencing data in a subset of infections suggests immune escape of the emerging BA.2.86 (JN.1) variant from recent prior infection (OR:2.6; 95%CI:1.1-6.3) and, although not statistically significant, from XBB.1.5 vaccination (OR:1.6; 95%CI:0.9-2.9).A monovalent mRNA vaccine targeting the SARS-CoV-2 Omicron XBB.1.5 subvariant (Comirnaty) was used in the 2023 Dutch COVID-19 vaccination campaign that started on October 2, 2023. Individuals aged ≥60 years, medical risk groups, pregnant women and healthcare workers were eligible for vaccination. Since September 2023, a new Omicron BA.2.86 sub-variant named JN.1 has emerged and quickly became dominant in the Netherlands and globally [1, 2]. BA.2.86 is genetically divergent from the previously circulating XBB variants, indicating potential for immune escape [3].We estimated vaccine effectiveness (VE) of XBB.1.5 vaccination against self-reported SARS-CoV-2 infection between 9 October 2023 and 9 January 2024 among adults aged 18-85 years who had previously received primary vaccination and at least one booster vaccination before 2 October 2023 and were eligible for XBB.1.5 vaccination. To assess potential immune escape by JN.1, we analyzed whether there was an association between XBB.1.5 vaccination or prior infection and the Omicron variant causing the infection (XBB vs. BA.2.86, including JN.1). The variant was determined by sequencing of viral genetic material present in positive lateral flow antigen self-tests.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://trialsearch.who.int/Trial2.aspx?TrialID=NL9279 Funding StatementThis study was funded by the Dutch Ministry of Health, Welfare and Sport.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The VASCO study protocol was approved by the not-for-profit independent Medical Ethics Committee of the Stichting Beoordeling Ethiek Biomedisch Onderzoek (BEBO), Assen, the Netherlands (NL76815.056.21).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymized data reported from this study can be obtained from the corresponding author upon request. The dataset may include individual data and a data dictionary will be provided. Data requests should include a proposal for the planned analyses. Data transfer will require a signed data sharing agreement.